Evopoint Biosciences Inc.
Clinical trials sponsored by Evopoint Biosciences Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced cancers: experimental drug XNW28012 enters human trials Results expected Dec 2026 (estimated)
- New drug candidate takes aim at Hard-to-Treat pancreatic cancer Results expected May 2027 (estimated)
-
New drug candidate takes aim at Hard-to-Treat pancreatic cancer
Disease control Recruiting nowResearchers are testing an experimental injectable drug called XNW28012 in people with metastatic pancreatic cancer that has worsened after two standard chemotherapy regimens. The phase III trial plans to enroll 226 adults and randomly assigns them in a 2:1 ratio to receive eithe…
Phase 3 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a targeted pill boost Chemotherapy's punch against a rare lymphoma?
Disease control Recruiting nowThis trial is investigating whether adding an experimental drug called XNW5004 to standard chemotherapy (CHOP or CHOEP) can help people newly diagnosed with peripheral T-cell lymphoma, an aggressive type of non-Hodgkin lymphoma. The study will enroll about 176 adults aged 18 to 7…
Phase 1/2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New pill shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests an experimental drug called XNW5004 in 65 people with follicular lymphoma (a slow-growing blood cancer) that has returned or stopped responding to at least three prior treatments. Participants take the drug twice daily for 28-day cycles. The main goal is to see h…
Phase 2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for advanced cancers: experimental drug XNW28012 enters human trials
Disease control Recruiting nowThis study tests a new drug called XNW28012 in people with advanced solid tumors (pancreatic, ovarian, cervical, or colorectal cancers) that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug shri…
Phase 1/2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for rare blood cancer: phase 3 trial of XNW5004 launches
Disease control Recruiting nowThis Phase 3 trial tests whether the experimental drug XNW5004 can help people with relapsed or refractory peripheral T-cell lymphoma, a rare and aggressive blood cancer. About 120 participants will receive either XNW5004 or the existing drug chidamide. The main goal is to see if…
Phase 3 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC